China
Africa
Explore chapters and articles related to this topic
Hydrastis canadensis (Goldenseal) and Lawsonia inermis (Henna)
Published in Azamal Husen, Herbs, Shrubs, and Trees of Potential Medicinal Benefits, 2022
Md. Mizanur Rahaman, William N. Setzer, Javad Sharifi-Rad, Muhammad Torequl Islam
Research suggests that berberine is one of the main active compounds in goldenseal that may help to treat herpes and chlamydia infections (https://www.healthline.com/health/goldenseal-cure-for-everything#benefits-uses). Vaginal chlamydia infections may be medicated with berberine-containing douches, vaginal suppositories, and also various types of oral goldenseal supplements (Vermani and Garg, 2002). One study demonstrated that goldenseal mixed with myrrh and thyme helped to treat oral herpes (Chin et al., 2010).
A Treatise on the Role of Herpesvirus in Neurodegeneration
Published in Abhai Kumar, Debasis Bagchi, Antioxidants and Functional Foods for Neurodegenerative Disorders, 2021
Bernard W. Downs, Manashi Bagchi, Bruce S. Morrison, Jeffrey Galvin, Steve Kushner, Debasis Bagchi, Kenneth Blum
HSV-1, an enveloped double-stranded DNA virus and a genome of approximately 152 kbp encoding more than 80 different open reading frames, is a neurotropic pathogen intricately associated with numerous clinical disorders starting from harmless skin infections to serious infection of the CNS. HSV-1 infection has been demonstrated as cases of oral herpes exhibited as cold sores or fever blisters, which affects over 50% of American adults. HSV-1 is the most predominant cause of sporadic encephalitis in adults and the leading cause of infectious blindness due to herpetic keratitis [42].
Mucosal immune responses to microbes in genital tract
Published in Phillip D. Smith, Richard S. Blumberg, Thomas T. MacDonald, Principles of Mucosal Immunology, 2020
HSV is an enveloped virus containing a double-stranded DNA (dsDNA) genome (approximately 150 kb) within the capsid. HSV is transmitted through mucosal contact through vaginal, penile, and oral routes. Even though HSV-1 is traditionally associated with oral herpes, adults without immunity to HSV-1 who practice oral sex are at risk for genital HSV-1 infection. In the developed countries, HSV-1 has replaced HSV-2 as the leading cause of genital herpes. The World Health Organization estimates that, in addition to the 417 million people with genital HSV-2 infections, there are approximately 140 million people living with genital HSV-1 infections. HSV-1 and HSV-2 enter the host through genital epithelia, and upon replication, enter the innervating ganglia where the virus establishes latent infection. Reactivation of the virus results in infection of the genital epithelia and external skin around the genitals and anus, leading to blisters followed by ulcerative lesions. However, most people infected with HSV are asymptomatic and unaware of their carrier status. Vertical transmission of HSV-2 from an infected mother to newborn leads to neonatal herpes, which is often lethal. HSV infection can be treated with the antiviral drug acyclovir, but this is not always effective, does not remove the latent viral pool and does not cure disease. There is no approved vaccines for HSV.
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candidate HN0037
Published in Expert Opinion on Therapeutic Patents, 2022
Christian Gege, Gerald Kleymann
More than half of the world’s population is chronically infected with herpesviruses. Herpes simplex virus (HSV) infections are the cause of herpes labialis (cold sores), genital herpes and sight-impairing keratitis, a major source of blindness worldwide. Less frequently, life-threatening disseminated disease (encephalitis and generalized viremia) can also occur, mainly in immunocompromised patients and neonates [1]. HSV-1 is commonly associated with oral herpes and HSV-2 with genital herpes. Drug development for HSV has been hampered in part by the success of acyclovir, a synthetic nucleoside analog targeting the viral polymerase with a good safety margin, albeit modest effectiveness. A drug that could avoid resistance, reduce outbreaks further or even clear latent virus to achieve a functional cure could have tremendous market success over generic acyclovir and other nucleoside analogues [2].
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
Published in Expert Opinion on Drug Safety, 2020
Ling Peng, Kui Xiao, Silvia Ottaviani, Justin Stebbing, Ying-Jie Wang
The significant SOCs were ‘Infections (SOC: 10,021,881),’ and ‘hepatobiliary disorders’ (SOC: 10,019,805)” (Table 2). Significant PTs of interest were shown in Table 3. Of note, ‘herpes zoster (PT: 10,019,974),’ ‘oral herpes (PT: 10,067,152),’ and ‘herpes virus infection (PT: 10,019,973)’ were detected in data mining. Thrombotic events have been reported in patients treated with baricitinib, which are indicated in the label for baricitinib. In our analysis, thrombosis as ‘pulmonary embolism (PT: 10,037,377),’ ‘deep vein thrombosis (PT: 10,051,055),’ and ‘retinal artery occlusion (PT: 10,038,827)’ were present, which correlated with findings from clinical trials. However, unexpected AEs were uncovered, including ‘pneumocystis jirovecii pneumonia (PT: 10,073,755),’ and ‘nephritis (PT: 10,049,765).’ Both gastrointestinal perforation (PT: 10,018,001) and ‘neutropenia (PT: 10,029,354),’ which are listed in drug label, did not meet the criteria for significant RORs.
Lack of direct association between oral mucosal lesions and SARS-CoV- 2 in a cohort of patients hospitalised with COVID-19
Published in Journal of Oral Microbiology, 2022
Gabriela Schwab, Michelle Palmieri, Rodrigo M. Zerbinati, Dmitry J. S. Sarmento, Thais Reis, Karem L. Ortega, Italo T. Kano, Rafael A. V. Caixeta, Bengt Hasséus, Dipak Sapkota, Roger Junges, Simone Giannecchini, André L. F. Costa, Sumatra M. C. P. Jales, José A. L. Lindoso, Camila Barros Gallo, Paulo H. Braz-Silva
With regard to oral mucosal alterations, Group 1 had three (1.9%) patients with pre-existing conditions such as pilous tongue, geographic tongue and inflammatory fibrous hyperplasia, all clinically diagnosed. Seven (4.5%) patients had opportunistic oral infections such as pseudomembranous candidiasis and herpes simplex, which were confirmed by means of exfoliative cytology and PCR for HSV-1 during hospitalisation (Figure 1). The definitive diagnosis of recurrent intra-oral herpes was not possible in only one patient, who had been discharged from the hospital before saliva collection. In Group 2, four (2.6%) patients had oral mucosal changes related to hospitalisation throughout the period of follow-up.